NICE Expands Cladribine Access for MS Patients
The National Institute for Health and Care Excellence (NICE) has recommended cladribine (Mavenclad, Merck Serono) for adults in England with relapsing-remitting multiple sclerosis (RRMS). This decision makes the NHS the first healthcare system in Europe to widely offer the at-home tablet for patients with active MS. The final draft guidance means cladribine is an option for … Read more